BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 23195018)

  • 41. Ganciclovir-resistant post-transplant cytomegalovirus infection due to combined deletion mutation at codons 595-596 of the UL97 gene.
    Leung PYM; Tran T; Testro A; Paizis K; Kwong J; Whitlam JB
    Transpl Infect Dis; 2019 Dec; 21(6):e13168. PubMed ID: 31498954
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The time course of development and impact from viral resistance against ganciclovir in cytomegalovirus infection.
    Cunha-Bang Cd; Kirkby N; Sønderholm M; Sørensen SS; Sengeløv H; Iversen M; Rasmussen A; Gustafsson F; Frederiksen CM; Kjaer J; Lepri AC; Lundgren JD
    Am J Transplant; 2013 Feb; 13(2):458-66. PubMed ID: 23282281
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The emergence of cytomegalovirus resistance to ganciclovir therapy in kidney transplant recipients.
    Nogueira E; Ozaki KS; Tomiyama H; Granato CF; Camara NO; Pacheco-Silva A
    Int Immunopharmacol; 2006 Dec; 6(13-14):2031-7. PubMed ID: 17161359
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Outcomes of transplant recipients treated with cidofovir for resistant or refractory cytomegalovirus infection.
    Mehta Steinke SA; Alfares M; Valsamakis A; Shoham S; Arav-Boger R; Lees L; Ostrander D; Forman MS; Shedeck A; Ambinder RF; Jones RJ; Avery RK
    Transpl Infect Dis; 2021 Jun; 23(3):e13521. PubMed ID: 33220125
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Identification of newly detected, drug-related HCMV UL97- and UL54-mutations using a modified plaque reduction assay.
    Fischer L; Sampaio KL; Jahn G; Hamprecht K; Göhring K
    J Clin Virol; 2015 Aug; 69():150-5. PubMed ID: 26209398
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Intra-host diversity of drug-resistant cytomegalovirus: A case report of cytomegalovirus infection after allogeneic hematopoietic cell transplantation.
    Jung JY; Nho D; Cho SY; Lee DG; Choi SM; Kim HJ; Kim M; Oh EJ
    J Infect Chemother; 2022 Oct; 28(10):1415-1418. PubMed ID: 35810104
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Resistant cytomegalovirus in intestinal and multivisceral transplant recipients.
    Timpone JG; Yimen M; Cox S; Teran R; Ajluni S; Goldstein D; Fishbein T; Kumar PN; Matsumoto C
    Transpl Infect Dis; 2016 Apr; 18(2):202-9. PubMed ID: 26853894
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dynamics of coexisting HCMV-UL97 and UL54 drug-resistance associated mutations in patients after haematopoietic cell transplantation.
    Göhring K; Wolf D; Bethge W; Mikeler E; Faul C; Vogel W; Vöhringer MC; Jahn G; Hamprecht K
    J Clin Virol; 2013 May; 57(1):43-9. PubMed ID: 23375740
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Absence of cytomegalovirus-resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients.
    Boivin G; Goyette N; Gilbert C; Roberts N; Macey K; Paya C; Pescovitz MD; Humar A; Dominguez E; Washburn K; Blumberg E; Alexander B; Freeman R; Heaton N; Covington E
    J Infect Dis; 2004 May; 189(9):1615-8. PubMed ID: 15116297
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Phenotype and Genotype Study of Novel C480F Maribavir-Ganciclovir Cross-Resistance Mutation Detected in Hematopoietic Stem Cell and Solid Organ Transplant Recipients.
    Santos Bravo M; Plault N; Sánchez Palomino S; Mosquera Gutierrez MM; Fernández Avilés F; Suarez Lledo M; Sabé Fernández N; Rovira M; Alain S; Marcos Maeso MÁ
    J Infect Dis; 2021 Sep; 224(6):1024-1028. PubMed ID: 33475730
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cytomegalovirus antiviral resistance associated with treatment induced UL97 (protein kinase) and UL54 (DNA polymerase) mutations.
    Scott GM; Isaacs MA; Zeng F; Kesson AM; Rawlinson WD
    J Med Virol; 2004 Sep; 74(1):85-93. PubMed ID: 15258973
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Phenotyping of cytomegalovirus drug resistance mutations by using recombinant viruses incorporating a reporter gene.
    Chou S; Van Wechel LC; Lichy HM; Marousek GI
    Antimicrob Agents Chemother; 2005 Jul; 49(7):2710-5. PubMed ID: 15980340
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir.
    Chou S
    Rev Med Virol; 2008; 18(4):233-46. PubMed ID: 18383425
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Successful ganciclovir treatment of primary cytomegalovirus infection containing the UL97 mutation N510S in an intestinal graft recipient.
    Bachmann R; Hamprecht K; Lange J; Ladurner R; Nadalin S; Jahn G; Königsrainer A; Heininger A
    Infection; 2013 Aug; 41(4):875-9. PubMed ID: 23546999
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Analysis and characterization of antiviral drug-resistant cytomegalovirus isolates from solid organ transplant recipients.
    Lurain NS; Bhorade SM; Pursell KJ; Avery RK; Yeldandi VV; Isada CM; Robert ES; Kohn DJ; Arens MQ; Garrity ER; Taege AJ; Mullen MG; Todd KM; Bremer JW; Yen-Lieberman B
    J Infect Dis; 2002 Sep; 186(6):760-8. PubMed ID: 12198609
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical impact of ganciclovir-resistant cytomegalovirus infections in solid organ transplant patients.
    Boivin G; Goyette N; Gilbert C; Humar A; Covington E
    Transpl Infect Dis; 2005; 7(3-4):166-70. PubMed ID: 16390409
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The impact of drug-resistant cytomegalovirus in pediatric allogeneic hematopoietic cell transplant recipients: a prospective monitoring of UL97 and UL54 gene mutations.
    Choi SH; Hwang JY; Park KS; Kim Y; Lee SH; Yoo KH; Kang ES; Ahn JH; Sung KW; Koo HH; Kim YJ
    Transpl Infect Dis; 2014 Dec; 16(6):919-29. PubMed ID: 25405808
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Detection of ganciclovir resistance after valacyclovir-prophylaxis in renal transplant recipients with active cytomegalovirus infection.
    Alain S; Hantz S; Scieux C; Karras A; Mazeron MC; Szelag JC; Imbert BM; Fillet AM; Gouarin S; Mengelle C; De Wilde A; Cogne N; Champier G; Rogez S; Legendre C; Denis F
    J Med Virol; 2004 Aug; 73(4):566-73. PubMed ID: 15221901
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Antiviral susceptibilities and analysis of UL97 and DNA polymerase sequences of clinical cytomegalovirus isolates from immunocompromised patients.
    Erice A; Gil-Roda C; Pérez JL; Balfour HH; Sannerud KJ; Hanson MN; Boivin G; Chou S
    J Infect Dis; 1997 May; 175(5):1087-92. PubMed ID: 9129070
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Quantitative changes in cytomegalovirus DNAemia and genetic analysis of the UL97 and UL54 genes in AIDS patients receiving cidofovir following ganciclovir therapy.
    Bowen EF; Cherrington JM; Lamy PD; Griffiths PD; Johnson MA; Emery VC
    J Med Virol; 1999 Aug; 58(4):402-7. PubMed ID: 10421408
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.